A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

🔬 Why This Trial Matters

SUCCESSOR-2 is a pivotal Phase 3 registration trial evaluating mezigdomide, a next-generation CELMoD (cereblon E3 ligase modulator), in combination with carfilzomib and dexamethasone versus the standard Kd doublet in relapsed/refractory multiple myeloma (RRMM). This trial represents a critical mid-line positioning strategy for mezigdomide, targeting patients who have received 1-3 prior lines of therapy including lenalidomide, a population where treatment options are narrowing but patients retain some therapeutic reserve. The trial's active-not-recruiting status with 606 enrolled participants and primary completion expected in mid-2026 positions this as one of multiple pivotal reads for the mezigdomide franchise, alongside SUCCESSOR-1 (monotherapy vs. pomalidomide) and other combination studies. Success here would establish mezigdomide as a foundational backbone agent in earlier relapse settings, significantly expanding its commercial opportunity beyond later-line salvage therapy and potentially capturing market share from lenalidomide-containing regimens in the second- and third-line settings.

📈 What the Readout Means for Investors

Investors should focus on the magnitude and statistical significance of the PFS benefit, with expectations likely calibrated around a hazard ratio of 0.60-0.70 (representing a 30-40% risk reduction) based on precedent from other CELMoD combination trials in similar populations. The bar for success requires not just statistical significance but clinically meaningful separation—ideally demonstrating median PFS improvement of at least 6-8 months over Kd alone, which typically delivers 9-12 months PFS in this patient population. Secondary endpoints including overall response rate, depth of response (MRD negativity), and duration of response will be critical for assessing durability and competitive differentiation, while safety data must demonstrate a manageable toxicity profile that doesn't substantially worsen the already challenging myelosuppression and cardiac risks associated with carfilzomib. A negative result would significantly constrain mezigdomide's commercial trajectory, potentially relegating it to later-line use only and raising questions about Bristol-Myers Squibb's ability to meaningfully compete in the post-lenalidomide RRMM market where Johnson & Johnson's teclistamab and other bispecifics are gaining traction.

🏁 Competitive Context

This trial positions mezigdomide directly against an intensifying competitive landscape dominated by bispecific antibodies and CAR-T therapies that are rapidly moving into earlier lines of RRMM treatment. Johnson & Johnson's teclistamab (BCMA-targeting bispecific) and Pfizer's elranatamab have demonstrated impressive response rates in heavily pretreated populations and are being evaluated in earlier-line settings, while CAR-T therapies like idecabtagene vicleucel and ciltacabtagene autoleucel have already shown superiority over standard regimens in earlier relapse. Mezigdomide's advantage lies in its oral convenience and potential for continuous dosing without the complex manufacturing and toxicity management required for cell therapies, but it must demonstrate PFS benefits comparable to bispecifics (which have shown median PFS in the 12-18 month range in similar populations) to remain commercially viable. The mid-2026 primary completion date places this readout approximately 2-3 years behind key bispecific data in earlier lines, meaning Bristol-Myers Squibb faces an uphill battle establishing mezigdomide's positioning unless the data show substantial superiority over current standards or identify specific patient subpopulations where oral CELMoDs offer advantages over injectable biologics.